Plaque Psoriasis (Psoriasis Vulgaris) is an indication for drug development with over 160 pipeline drugs currently active. According to GlobalData, preregistered drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 93.02% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Plaque Psoriasis (Psoriasis Vulgaris) compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Plaque Psoriasis (Psoriasis Vulgaris) overview

Plaque psoriasis, also known as psoriasis vulgaris, is the most common form of psoriasis, a chronic skin condition characterized by the rapid buildup of skin cells. It results from an overactive immune system, causing skin cells to accumulate on the surface, forming thick, scaly, and often itchy patches or plaques. These patches can vary in size and typically have a silvery-white scale. Plaque psoriasis commonly affects areas like the elbows, knees, scalp, and lower back, but it can occur anywhere on the body. The condition is not contagious, and its severity can vary from mild to severe. Treatment options include topical creams, phototherapy, systemic medications, and biologics, aimed at managing symptoms and controlling inflammation.

For a complete picture of PTSR and LoA scores for drugs in Plaque Psoriasis (Psoriasis Vulgaris), buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.